Management of Male Breast Cancer in the United States: A Surveillance, Epidemiology and End Results Analysis

Fields, Emma C.; DeWitt, Peter; Fisher, Christine M.; Rabinovitch, Rachel

doi:10.1016/j.ijrobp.2013.07.016

Cited by 53 publications

(45 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors concluded that BCS for early stage MBC has outcomes similar to that of mastectomy for MBC. This study validated a similar SEER database review in 2013 …”

Section: Discussionsupporting

confidence: 74%

Breast conservation for male breast cancer: Case report of intraoperative radiation

et al. 2017

View full text Add to dashboard Cite

Male breast cancer (MBC) comprises <1% of all breast cancers in the United States.MBC is typically treated with total mastectomy while the majority of female breast cancer is treated with breast conservation therapy combined with various forms of radiation. One method that has developed over the last two decades is the use of intraoperative radiation therapy (IORT) as a type of accelerated partial breast irradiation to direct the treatment field to the tumor bed. Since overall prognosis and systemic therapy recommendations for MBC are similar to breast cancer in women, we describe the first case of MBC treated with BCS and IORT. Our patient is a 62-year-old male who was found to have a right breast 1.6 cm palpable mass at the 10:00 position 1 cm radially from the nipple. Core biopsy demonstrated invasive ductal carcinoma, moderately differentiated, estrogen and progesterone receptor positive, and Her 2 Negative. The patient had a strong desire for breast conservation, and needed to minimize daily radiation treatments due to his work schedule. After discussion among our multidisciplinary tumor board, we felt this patient to be suitable for BCS and IORT given his age, favorable tumor subtype, size, and clinically early stage breast cancer. A right axillary sentinel lymph node biopsy and central lumpectomy was performed. The INTRABEAM device (Carl Zeiss Meditec, Oberkochen, Germany) was utilized for radiation delivery.The patient had negative margins on his final pathology. The postoperative course was uneventful and at the 6 month follow-up visit there were no issues and he had an excellent cosmetic outcome. BCS and IORT is an option in appropriately selected male patients with favorable subtype early stage breast cancer. K E Y W O R D Sbreast cancer, breast conservation surgery, intraoperative radiation, male breast cancer

show abstract

“…The authors concluded that BCS for early stage MBC has outcomes similar to that of mastectomy for MBC. This study validated a similar SEER database review in 2013 …”

Section: Discussionsupporting

confidence: 74%

Breast conservation for male breast cancer: Case report of intraoperative radiation

et al. 2017

View full text Add to dashboard Cite

show abstract

“…One hundred and seventy-one articles were identified and assessed. Twenty-nine of them met the inclusion criteria ( Figure 1 and Table I), involving 10,965 men diagnosed with breast cancer (6,. No prospective study had been published.…”

Section: Resultsmentioning

confidence: 99%

“…Average follow-up was between 7 and 314 months (median=60 months). The number of patients per study was between 40 and 664 (mean=82), except for three studies utilizing national databases (with 4,276, 1,933, and 1,337 patients, respectively) (6,18,34). Patients were treated during the period 1960-2013.…”

Section: Resultsmentioning

confidence: 99%

“…Withholding radiotherapy was either advocated in females with good prognostic factors or males with poor performance status (21). Indications and techniques of radiation therapy were not systematically reported and varied depending on authors/countries and periods (with the use of cobalt and orthovoltage in earlier periods) (6,20,35). Müller et al mentioned an electron beam rotational technique for the chest wall (27).…”

Section: Resultsmentioning

confidence: 99%

“…Breast cancer in males is infrequent, representing 1% of all breast carcinomas, and less than 1% of all male cancers (1, 2), even if its incidence seems to be increasing (3)(4)(5)(6)(7). All studies regarding male breast cancer (MBC) are retrospective and specific recommendations are sparse.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Should Adjuvant Radiation Therapy Be Systematically Proposed for Male Breast Cancer? A Systematic Review

Jardel

Vignot²,

Cutuli

et al. 2018

View full text Add to dashboard Cite

Breast cancer in males is infrequent, representing 1% of all breast carcinomas, and less than 1% of all male cancers (1, 2), even if its incidence seems to be increasing (3-7). All studies regarding male breast cancer (MBC) are retrospective and specific recommendations are sparse. The general management of non-metastatic MBC is usually based on guidelines for female breast cancer (FBC). Surgery, chemotherapy and hormonal therapy are based on classical prognostic factors. After mastectomy, which represents the majority of cases, locoregional irradiation for MBC remains controversial. Some institutions recommend systematic postmastectomy irradiation considering that MBC is intrinsically more aggressive than FBC and that the ratio of tumor size to gland could lead to minimal surgical margins; others suggest that the natural history of MBC resembles that of postmenopausal female breast cancer and that the aggressiveness is biased by a more advanced stage at diagnosis (1, 2, 4). Institutions base their recommendations for MBC based on data established for females. We evaluated clinical practices and outcomes with respect to radiation therapy in MBC treated with locoregional irradiation in the adjuvant setting using a systematic literature review. Materials and MethodsOur systematic review of the literature was based on the Preferred Reporting Items for Systematic Reviews and meta-Analysis (PRISMA) recommendations (http://www.prisma-statement.org/). Data were selected from a search on PubMed during the period 1976 to 2017 and from references in identified articles, using the following search terms: "breast cancer", "men", "male", "radiotherapy"; articles published in English or French were included. Relevant articles were selected with the following inclusion criteria: non metastatic MBC, an original study with more 23This article is freely accessible online.

show abstract

Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century

Yadav

Karam

Riaz

et al. 2019

Cancer

109

103

View full text Add to dashboard Cite

Background Male breast cancer (MBC) is a rare disease for which there is limited understanding of treatment patterns and prognostic factors. Methods Men with TNM stage I to stage III breast cancer diagnosed between 2004 and 2014 in the National Cancer Data Base were included. Trends in treatment modalities were described using the average annual percentage change (AAPC) and estimated using Joinpoint software for the analysis of trends. Kaplan‐Meier curves and the multivariate Cox proportional hazards regression model were used to compare survival between subgroups and to identify prognostic factors. Results A total of 10,873 MBC cases were included, with a median age at diagnosis of 64 years. Breast‐conserving surgery was performed in 24% of patients, and 70% of patients undergoing breast conservation received radiotherapy. Approximately 44% of patients received chemotherapy, and 62% of patients with estrogen receptor–positive disease received endocrine therapy. Oncotype DX was ordered in 35% of patients with lymph node–negative, estrogen receptor–positive/human epidermal growth factor receptor 2 (HER2)‐negative tumors. During the study period, there was a significant increase in the rates of total mastectomy, contralateral prophylactic mastectomy, radiotherapy after breast conservation, ordering of Oncotype DX, and the use of endocrine therapy (P < .05). On multivariate analysis, factors found to be associated with worse overall survival were older age, black race, higher Charlson Comorbidity Index, high tumor grade and stage of disease, and undergoing total mastectomy. Residing in a higher income area; having progesterone receptor–positive tumors; and receipt of chemotherapy, radiotherapy, and endocrine therapy were associated with better overall survival. Conclusions Despite the lack of prospective randomized trials in patients with MBC, the results of the current study demonstrated that the treatment of this disease has evolved over the years. These findings further the understanding of the modern treatment and prognosis of MBC, and identify several areas for further research.

show abstract

Management of Male Breast Cancer in the United States: A Surveillance, Epidemiology and End Results Analysis

Cited by 53 publications

References 18 publications

Breast conservation for male breast cancer: Case report of intraoperative radiation

Breast conservation for male breast cancer: Case report of intraoperative radiation

Should Adjuvant Radiation Therapy Be Systematically Proposed for Male Breast Cancer? A Systematic Review

Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century

Contact Info

Product

Resources

About